Anastrozole may be superior to Tamoxifen as adjuvant treatment for postmenopausal patients with breast cancer

Clinical Breast Cancer

Volumn 2, Issue 4, 2002, Pages 269-271

  Fisher, Maxine D ^a   O'Shaughnessy, Joyce ^a   Sparano, Joseph A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HOT FLUSH; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; WEIGHT GAIN;

EID: 0036185039     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-8209(11)70424-4     Document Type: Article

References (5)

1. Role of adjuvant endocrine therapy in earlystage breast cancer
2. Aromatase inhibitory in advanced breast cancer: Mechanism of action and clinical implications
3. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study
4. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial Arimidex Study Group
5. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal (PM) women